Understand the source comparison
Kisspeptin Myths Debunked: Evidence Comparison
This table compares common kisspeptin myths debunked against published clinical evidence, mechanisms, and trial outcomes. Kisspeptin is a banned steroid Acts on KISS1R in hypothalamus, not androgen receptors; not on WADA list No anabolic effects reported in 17
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- This table compares common kisspeptin myths debunked against published clinical evidence, mechanisms, and trial outcomes.
- Kisspeptin is a banned steroid
- Acts on KISS1R in hypothalamus, not androgen receptors; not on WADA list
- No anabolic effects reported in 17 RCTs (JCEM 2023 review)
- Not a steroid, not banned. Upstream neuroendocrine signaling only
- Directly raises testosterone in all men
- Stimulates GnRH → LH → testosterone; negative feedback limits effect
- Eugonadal men show minimal testosterone change (Imperial 2014 trial)
- Only restores testosterone in hypogonadal men; plateaus at physiological range
- Builds muscle and enhances performance
- Zero direct action on muscle tissue or androgen receptors
- No lean mass or strength gains in any published trial
- No anabolic activity. Mechanism is neuroendocrine, not tissue-level
- Guarantees fertility and pregnancy
- Triggers GnRH pulse if hypothalamus responsive; downstream depends on gonad function
- 95% ovulation trigger success in IVF (Lancet 2018); 68% sperm production in CHH men (2019 study)
- Effective for hypothalamic infertility only; doesn't reverse gonadal failure
- Safe for long-term daily use without monitoring
- Chronic receptor activation may desensitize KISS1R; no long-term safety trials beyond 24 weeks
- Tachyphylaxis observed in animal models; human safety data limited to 6-month trials
- Requires medical supervision; long-term effects unknown
- Works the same as hCG or clomiphene
- Different receptor and mechanism: KISS1R vs LH receptor or estrogen receptor modulation
- Lower OHSS risk than hCG (1.7% vs 13.5%, Lancet 2018); different feedback profile than clomiphene
- Unique upstream mechanism. Not interchangeable with other fertility agents